Lupin Offloads Kyowa Pharma For $525m But Not Exiting Japan
$300m Net From PE Deal Gives Leeway For Acquisitions, Organic Growth
Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.
